<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02530905</url>
  </required_header>
  <id_info>
    <org_study_id>4045-101</org_study_id>
    <nct_id>NCT02530905</nct_id>
  </id_info>
  <brief_title>Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration, Safety, Tolerability, and Pharmacokinetics Study Followed by an Open-Label Safety and Efficacy Evaluation of SRP-4045 in Advanced-Stage Patients With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarepta Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sarepta Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human dose-titration and open-label extension study to assess safety,
      tolerability, and pharmacokinetics of SRP-4045 in advanced-stage Duchenne muscular dystrophy
      (DMD) patients with deletions amenable to exon 45 skipping.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, placebo-controlled dose-titration study to assess safety, tolerability,
      and pharmacokinetics of 4 dose levels of SRP-4045 in genotypically confirmed advanced-stage
      DMD patients with deletions amenable to exon 45 skipping.

      After completion of the dose-titration portion of the study and SRP-4045 is determined to be
      safe, all patients will be evaluated on open-label SRP-4045 for the duration of the study.

      Safety, including adverse event monitoring, routine laboratory assessments, and cardiac
      testing will be monitored through the duration of the dose-titration and open-label portions
      of the study.

      Clinical efficacy will be assessed at regularly scheduled study visits via quality of life
      questionnaires and tests of pulmonary and upper extremity function through the duration of
      the dose-titration and open-label portions of the trial.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Approximately 12 Weeks (double-blind dose titration)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug concentration in plasma</measure>
    <time_frame>Approximately 12 Weeks (double-blind dose titration)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>SRP-4045 (double-blind dose titration)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 8 genotypically confirmed DMD patients amenable to exon 45 skipping</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (double-blind dose titration)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Approximately 4 genotypically confirmed DMD patients amenable to exon 45 skipping.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRP-4045 (open label)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 12 DMD patients who completed the double-blind dose titration part of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SRP-4045</intervention_name>
    <arm_group_label>SRP-4045 (double-blind dose titration)</arm_group_label>
    <arm_group_label>SRP-4045 (open label)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo (double-blind dose titration)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Genotypically confirmed DMD (amenable to exon 45 skipping).

          -  Stable cardiac and pulmonary function.

          -  Limited or no ambulation.

          -  On a stable dose of oral corticosteroids for at least 24 weeks OR has not received
             corticosteroids for at least 24 weeks.

        Exclusion Criteria:

          -  Current or previous treatment with the experimental agents SMT C1100 (BMN-195) or
             PRO045.

          -  Other experimental treatment in the past 12 weeks.

          -  If on cardiac medication, must be on a stable dose for the past 12 weeks.

          -  Major surgery within the past 3 months.

        Other inclusion/exclusion criteria apply.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Lu, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sarepta Therapeutics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine Stehman-Breen, MD, MS</last_name>
    <role>Study Director</role>
    <affiliation>Sarepta Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kennedy Krieger Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2015</study_first_submitted>
  <study_first_submitted_qc>August 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2015</study_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne muscular dystrophy</keyword>
  <keyword>Exon Skipping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

